Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD 202 receives approval to start Phase 1 therapeutic trial

Friday, December 20, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has received approval to initiate a Phase 1 therapeutic trial for RAD 202, targeting the B7H3 protein. This approval is a crucial milestone in the drug's development process, indicating progress in clinical research. The trial aims to evaluate the safety and efficacy of RAD 202 in patients.
Price reaction · baseline $4.39 (2024-12-20T15:28:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD 202 has received approval to start a Phase 1 therapeutic trial.
  • The trial targets B7H3, indicating a focused approach to treatment.
  • This marks a significant step in the development of RAD 202.

Full Press Release Details

• Announcements
• Price Sensitive
• December 20, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• March 28, 2022
• Announcements
• March 26, 2024
• Announcements
• June 25, 2024
• Announcements
• October 9, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD 202?

RAD 202 is a therapeutic candidate developed by Radiopharm Theranostics targeting B7H3.

What trial has RAD 202 been approved for?

RAD 202 has been approved to start a Phase 1 therapeutic trial.

What is the target of RAD 202?

RAD 202 targets the B7H3 protein in its therapeutic approach.

Who approved the Phase 1 trial for RAD 202?

The Phase 1 trial for RAD 202 was approved by the US FDA.

Tags: RADX Viatris Investor Conferences Healthcare RAD 202 Phase 1 trial B7H3 Radiopharm Theranostics FDA approval
Last updated: Dec 20, 2024